Status | Study |
Available |
Study Name: Expanded Access Protocol Using I131-MIBG Condition: Neuroblastoma Pheochromocytoma Parag Date: 2012-05-01 Interventions: Radiation: I-131 MIBG The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 |
Completed |
Study Name: A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors Condition: Pheochromocytoma Paraganglioma Date: 2011-08-08 Interventions: Radiation: 131I-MIBG Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rock |
Available |
Study Name: Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma Condition: Pheochromocytoma Paraganglioma Date: 2011-06-13 Interventions: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG) Therapeutic 131I-MIBG will be synthesized at Nuclear Di |
Recruiting |
Study Name: First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma Condition: Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL) Date: 2011-06-09 Interventions: Drug: Sunitinib sunitinib 37.5 |
Terminated |
Study Name: Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma Condition: Extra-Adrenal Paraganglioma Metastatic Adrenal Gland Pheochromo Date: 2011-04-21 Interventions: Other: Laboratory Biomarker Analysis |
Available |
Study Name: 131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Paraganglioma/Pheochromocytoma Condition: Neuroblastoma Childhood Metastatic Pheochromocytoma Date: 2010-07-13 Interventions: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG) |
Completed |
Study Name: RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid Condition: Pheochromocytoma Extra-adrenal Paraganglioma Date: 2010-05-31 Interventions: Drug: RAD001 RAD001 10 mg daily po medication. |
Completed |
Study Name: Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma Condition: Pheochromocytoma Paraganglioma Date: 2009-11-17 Interventions: Other: plasma EM66 & CgA levels assessment |
Terminated |
Study Name: Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma Condition: Pheochromocytoma Paraganglioma Date: 2009-05-29 |
Active, not recruiting |
Study Name: A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Condition: Pheochromocytoma Paraganglioma Date: 2009-04-01 Interventions: Radiation: Ultratrace® Iobenguane I131 Each subject will be administered 3 mCi to 6 mCi Ultratrace& |